Myocardial fibrosis combined with NT-proBNP improves the accuracy of survival prediction in ADHF patients.
Aged
Biomarkers
/ blood
Cause of Death
Female
Fibrosis
Heart Failure
/ blood
Humans
Interleukin-1 Receptor-Like 1 Protein
/ blood
Male
Middle Aged
Myocardium
/ pathology
Natriuretic Peptide, Brain
/ blood
Peptide Fragments
/ blood
Predictive Value of Tests
Procollagen
/ blood
Prognosis
Prospective Studies
Risk Assessment
Risk Factors
Time Factors
Biomarkers
Heart failure
Myocardial fibrosis
Prognosis
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
28 05 2021
28 05 2021
Historique:
received:
27
02
2021
accepted:
21
05
2021
entrez:
29
5
2021
pubmed:
30
5
2021
medline:
22
12
2021
Statut:
epublish
Résumé
Soluble suppression of tumorigenesis-2 (sST2), Procollagen Type III N-Terminal Peptid (PIIINP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) have been verified their role in predicting survival in acutely decompensated heart failure (ADHF). However, whether their combination could improve more specific and sensitive prognostic information than NT-proBNP alone remains unclear. This was a prospective study, in which 217 ADHF patients at admission were enrolled from November 2018 and August 2019 (mean age 66.18 years ± 13.60, 63.98% male). The blood samples were collected to measure the concentrations of NT-proBNP, sST2 and PIIINP in the first 24 h of hospitalizations. All-cause mortality was registered for all patients after they were discharge over a median period of 339 days. In univariate Cox analysis, the three biomarkers were predictive of short-term mortality of ADHF patients. After adjusted for some clinical variables including age, admission systolic blood pressure, peripheral edema on admission, history of chronic obstructive pulmonary disease, admission sodium < 135 mmol/L, admission hemoglobin, NT-proBNP, sST2 and PIIINP was significantly associated with the poor outcome (hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.14-1.53, P < 0.01; HR 1.21, 95% CI 1.03-1.43, P = 0.020; HR 1.40, 95% CI 1.08-1.81, P = 0.011). After added with Log2 PIIINP, but not Log2 sST2, the area under the curves (AUC) in the model of clinical variables and Log2 NT-proBNP could increase from 0.79 to 0.85 (95% CI 0.0071-0.10, P = 0.024). Furthermore, compared with the model of clinical variables, Log2 NT-proBNP, the improvement in the prognostic model of clinical variables, Log2 NT-proBNP and Log2 PIIINP had statistical significance [net reclassification improvement (NRI) 0.31, P = 0.018; integrated discrimination improvement (IDI) 0.068, P < 0.01]. NT-proBNP, sST2 and PIIINP are independent prognostic factors for all-cause mortality in ADHF patients. Furthermore, the combination of NT-proBNP and PIIINP may provide incremental prognostic value over NT-proBNP in the survival of ADHF patients.
Sections du résumé
BACKGROUND
Soluble suppression of tumorigenesis-2 (sST2), Procollagen Type III N-Terminal Peptid (PIIINP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) have been verified their role in predicting survival in acutely decompensated heart failure (ADHF). However, whether their combination could improve more specific and sensitive prognostic information than NT-proBNP alone remains unclear.
METHODS
This was a prospective study, in which 217 ADHF patients at admission were enrolled from November 2018 and August 2019 (mean age 66.18 years ± 13.60, 63.98% male). The blood samples were collected to measure the concentrations of NT-proBNP, sST2 and PIIINP in the first 24 h of hospitalizations. All-cause mortality was registered for all patients after they were discharge over a median period of 339 days.
RESULTS
In univariate Cox analysis, the three biomarkers were predictive of short-term mortality of ADHF patients. After adjusted for some clinical variables including age, admission systolic blood pressure, peripheral edema on admission, history of chronic obstructive pulmonary disease, admission sodium < 135 mmol/L, admission hemoglobin, NT-proBNP, sST2 and PIIINP was significantly associated with the poor outcome (hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.14-1.53, P < 0.01; HR 1.21, 95% CI 1.03-1.43, P = 0.020; HR 1.40, 95% CI 1.08-1.81, P = 0.011). After added with Log2 PIIINP, but not Log2 sST2, the area under the curves (AUC) in the model of clinical variables and Log2 NT-proBNP could increase from 0.79 to 0.85 (95% CI 0.0071-0.10, P = 0.024). Furthermore, compared with the model of clinical variables, Log2 NT-proBNP, the improvement in the prognostic model of clinical variables, Log2 NT-proBNP and Log2 PIIINP had statistical significance [net reclassification improvement (NRI) 0.31, P = 0.018; integrated discrimination improvement (IDI) 0.068, P < 0.01].
CONCLUSIONS
NT-proBNP, sST2 and PIIINP are independent prognostic factors for all-cause mortality in ADHF patients. Furthermore, the combination of NT-proBNP and PIIINP may provide incremental prognostic value over NT-proBNP in the survival of ADHF patients.
Identifiants
pubmed: 34049488
doi: 10.1186/s12872-021-02083-6
pii: 10.1186/s12872-021-02083-6
pmc: PMC8164226
doi:
Substances chimiques
Biomarkers
0
IL1RL1 protein, human
0
Interleukin-1 Receptor-Like 1 Protein
0
Peptide Fragments
0
Procollagen
0
pro-brain natriuretic peptide (1-76)
0
procollagen Type III-N-terminal peptide
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
264Références
Eur J Immunol. 2012 Jul;42(7):1863-9
pubmed: 22585662
Eur Heart J. 2014 Feb;35(7):419-25
pubmed: 24227810
J Am Heart Assoc. 2016 Aug 01;5(8):
pubmed: 27481133
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
J Am Coll Cardiol. 2008 Dec 16;52(25):2166-74
pubmed: 19095135
J Am Coll Cardiol. 2019 Mar 12;73(9):1016-1025
pubmed: 30846095
J Am Coll Cardiol. 2008 Oct 28;52(18):1458-65
pubmed: 19017513
Eur J Heart Fail. 2011 Jul;13(7):718-25
pubmed: 21551163
Radiology. 1982 Apr;143(1):29-36
pubmed: 7063747
J Card Fail. 2010 Feb;16(2):128-34
pubmed: 20142024
Circulation. 2017 Aug 8;136(6):e137-e161
pubmed: 28455343
JACC Heart Fail. 2014 Apr;2(2):148-58
pubmed: 24720923
Circ Heart Fail. 2009 Jul;2(4):311-9
pubmed: 19808354
J Card Fail. 2016 Sep;22(9):692-9
pubmed: 26721774
Am J Cardiol. 1995 May 1;75(14):913-8
pubmed: 7733000
Circulation. 2005 Nov 8;112(19):2940-5
pubmed: 16275882
Heart. 2014 Jan;100(2):115-25
pubmed: 24179162
Medicine (Baltimore). 2017 Apr;96(14):e6558
pubmed: 28383431
J Am Coll Cardiol. 2010 Jan 19;55(3):243-50
pubmed: 20117403
Int J Cardiol. 2013 Oct 3;168(3):2120-6
pubmed: 23395457
Front Physiol. 2018 Jun 26;9:758
pubmed: 29997521
Circ Heart Fail. 2018 Dec;11(12):e005488
pubmed: 30562096
Eur J Heart Fail. 2015 Aug;17(8):809-17
pubmed: 25921853
Growth Horm IGF Res. 2007 Aug;17(4):288-96
pubmed: 17383209
Int J Cardiovasc Imaging. 2017 Dec;33(12):1915-1920
pubmed: 28664478
J Am Coll Cardiol. 2004 May 5;43(9):1590-5
pubmed: 15120816
Eur Heart J. 2019 Oct 21;40(40):3345-3352
pubmed: 31093657
Circ Heart Fail. 2011 Sep;4(5):628-36
pubmed: 21743005
Clin Chim Acta. 2009 Nov;409(1-2):33-40
pubmed: 19699192
Circ Heart Fail. 2013 May;6(3):606-19
pubmed: 23616602
Am J Kidney Dis. 2003 Mar;41(3):571-9
pubmed: 12612980
Heart Fail Rev. 2014 Aug;19(4):453-70
pubmed: 25062653